EKTA SHIRBHATE

Research Scholar

Work Experience

I have completed my M. Pharm research project entitled “Design and synthesis of novel triazole based hydroxamic acid for their anticancer activity” under the guidance of Dr. Harish Rajak, Sr. Assistant Professor, Guru Ghasidas University, Bilaspur. My research interest is "Design and development of novel histone deacetylase inhibitors as anticancer agent".

Area of Specialization

 Computer Aided Drug Design (CADD)  Molecular modelling  Small-molecule drug discovery  Synthesis in the area of development of HDAC inhibitory molecules  Data Interpretation (IR, NMR, Mass spectroscopy)

Projects & Patents

NA

Education

M.Pharm, B.Pharm.

Achievments/Awards/Honors

First rank in Poster presentation.

Publications

 Shirbhate E, Sahu D, Patel P, Patel VK, Veerasamy R, Sharma PC, Rajak H. Searching for potential HDAC2 inhibitors: Structure-activity relationship studies on Indole-based hydroxamic acids as an anticancer agent. Lett. Drug Des. Discov, 2020, 17(7), 905-917. (IF: 1.099)  Shirbhate E, Patel P, Patel VK, Veerasamy R, Sharma PC, Rajak H. The combination of histone deacetylase inhibitors and radiotherapy: a novel promising approach for cancer treatment. Future Oncol., 2020. doi: 10.2217/fon-2020-0385 (IF: 3.674)  Divya, Shirbhate E, Patel VK, Patel P, Veerasamy R, Jawaid T, Kamal M, Rajak H. Lead identification of hydroxamate derivative as selective HDAC inhibitor using computational approaches. Indian Drugs, 2020, 57(7), 26-39. (IF:0.117)  Shirbhate E, Patel P, Patel VK, Veersamy R, Sharma PC, Sinha BN, Rajak H. Synthetic and semi-synthetic drugs as promising therapeutic option for the treatment of COVID-19. Mini Rev. Med. Chem., 2021, 21(8), 1004-1016. (IF: 3.737)  Shirbhate E, Divya, Patel P, Patel VK, Veerasamy R, Rajak H. Exploration of anticancer potential of hydroxamate derivatives as selective HDAC8 inhibitors using integrated structure and ligand based molecular modeling approach. Indian J. Chem., 2021. (IF:0.456)  Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, Kesharwani P, Rajak H. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol. Rep., 2021, 73(6), 1539-1550. (IF: 3.919)  Patel VK, Shirbhate E, Patel P, Veerasamy R, Sharma PC, Rajak H. Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent. Beni Suef Univ. J. Basic Appl. Sci., 2021, 10(1), 78. (IF:3.07)  Shirbhate E, Veerasamy R, Boddu SHS, Tiwari AK, Rajak H. histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment. Drug Discovery Today, 2022. doi: 10.1016/j.drudis.2022.02.009 (IF: 8.369)  Shirbhate E, Patel VK, Tiwari P, Kore R, Veerasamy R, Rajak H. Combination therapy for the treatment of Alzheimer’s Disease: Recent Progress and Future Prospects. Curr. Topics Med. Chem., 2022. doi: 10.2174/1568026622666220907114443 (IF: 3.57)  Shirbhate E, Pandey J, Patel VK, Veerasamy R, Rajak H. Exploration of structure activity relationship using integrated structure and ligand based approach: Hydroxamic acid based HDAC inhibitors and cytotoxic agents. Turkish J. Pharm. Sci., 2023, 20(4), 270-284. doi: 10.4274/tjps.galenos.2022.1269 (IF: 0.44)  Patel VK, Shirbhate E, Tiwari P, Kore R, Veerasamy R, Mishra A, Rajak H. Multi-targeted HDAC inhibitors as anticancer agents: Current status and future prospective. Curr. Med. Chem., 2023, 30(24), 2762-2795. doi: 10.2174/0929867329666220922105615. (IF:4.74)  Patel P, Shrivastava SK, Sharma P, Kurmi BD, Shirbhate E, Rajak K. Hydroxamic acid derivatives as selective HDAC3 inhibitors: Computer-aided drug design strategies. J. Biomol. Struct. Dyn., 2024, 42(1), 362-383. doi:10.1080/07391102.2023.2192804. (IF:5.235)  Shirbhate E, Singh V, Jahriya V, Mishra A, Veerasamy R, Tiwari AK, Rajak H. Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment. Eur. J. Med. Chem., 2024, 263, 115938. doi: 10.1016/j.ejmech.2023.115938. (IF:7.088)  Shirbhate E, Singh V, Kore R, Vishwakarma S, Veerasamy R, Tiwari AK, Rajak H. The role of cytokines in activation of tumour promoting pathways and emergence of cancer drug resistance. Curr. Topics Med. Chem., 2024. (Accepted) (IF: 3.57) Book Chapter  Patel VK, Shirbhate E, Rajak H. (2022). Coronavirus reinfections: An outlook on evidences and effects. In A. Kaklauskas, A. Abraham, K. Okoye, S. Guggari (Ed.). Lessons from COVID-19: Impact on healthcare systems and technology. (pp. 19-40). London, UK: Academia Press Elsevier.  Kore R, Tiwari P, Patel VK, Shirbhate E, Veerasamy R, Mishra A, Rajak H. Memantine and glutamate antagonists in the treatment of Alzheimer’s disease: Current updates. In Dileep Kumar, Prashant Tiwari (Ed.). Enzymatic targets for drug discovery against Alzheimer’s Disease. (pp. 111-120). Singapore: Bentham Books. Details of Patent :  Title: A process for synthesizing n-(6,12-dioxo-6,12 dihydroindolo[2,1-b]quinazolin-8-yl)benzenesulfonamide derivatives for anticancer activities. Application number: 2021/10563, Published on: 29.06.2022 (South African patent)  Title: Design, Synthesis and Anticancer activity of novel sulfamoyl based hydroxamates. Application number: 202023105438, Published on: 29.09.2023 (German patent)